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Abstract Treatment of human gastric cancer TMK-1 cells with 
transcription and translation inhibitors rapidly triggered cell 
apoptosis. Along with cell apoptosis, the Bcl-xs level was 
markedly upregulated suggesting a crucial role of this protein 
in promoting the apoptotic process. In the presence of 
dexamethasone, however, cell apoptosis was greatly attenuated 
as demonstrated by DNA histogram shift and DNA fragmenta-
tion. Studies using the glucocorticoid receptor antagonist Rl 486 
indicated that attenuation of apoptosis was mediated through 
glucocorticoid receptors. Dexamethasone not only suppressed the 
apoptosis-associated upregulation of Bcl-xs but also enhanced 
the basal level of BC1-XL in the cells. In addition, bcl-x mRNA 
stability was significantly extended in the presence of dexa-
methasone. These results indicate that dexamethasone exerted a 
protective effect and delayed apoptosis of TMK-1 cells by 
modulating bcl-x gene expression. 
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1. Introduction 
Apoptosis plays an important role in cell proliferation, or-
gan involution, tumor development, and as a cellular response 
to a variety of stress insults. Apoptosis is an active, irrever-
sible process by which cells die as a result of activation of an 
internally encoded cell death program [1,2]. Much effort has 
recently gone into identifying the genes responsible for apop-
tosis induction and suppression [3]. Among them, the prod-
ucts of the bcl-2 gene family regulate conserved cellular path-
ways for apoptosis of different cells in response to a variety of 
apoptotic stimuli. Some of the members of this gene family 
are cell death inhibitors, such as Bcl-2, BC1-XL, Mcl-1, and Bfl-
1, whereas others are promoters of cell death, such as Bax, 
Bad, Bak, and Bcl-xs [2,4,5]. These proteins can physically 
interact with each other to form homo- or heterodimers that 
affect the susceptibility of cells to apoptotic stimuli. It has 
been suggested that the apoptotic threshold of a cell may be 
the result of a dynamic balance between these positive and 
»Corresponding author. Fax: +886 (2) 368-1354. 
Abbreviations: Dex, dexamethasone; ActD, actinomycin D; DRB, 
5,6-dichloro-l-ß-D-ribofuranosyl benzimidazole; CHX, cycloheximide; 
GAPDH, glyceraldehyde 3-phosphodehydrogenase; PI, propidium 
iodide 
negative regulators of apoptosis [6]. The bcl-x gene is unique 
in that it encodes two proteins, BC1-XL and Bcl-xg, by alter-
natively spliced transcripts [5]. Recent studies have indicated 
that overexpression of Bcl-2 or BC1-XL protects cells against 
apoptosis induced by a wide range of stimuli [2]. In contrast, 
the short form, Bcl-xs, functions as a dominant negative in-
hibitor of Bcl-2 and BC1-XL, and promotes cell apoptosis [5,6]. 
It has been shown that overexpression of Bcl-xg sensitized 
cultured cells or tumor to apoptosis [7,8]. Bax and Bcl-xs 
expression have been shown to be induced at the onset of 
apoptosis in involuting mammary epithelial cells [9]. Our pre-
vious study also demonstrated that the apoptosis in TMK-1 
cells triggered by the transcription inhibitor actinomycin D 
(ActD), the RNA polymerase II inhibitor 5,6-dichloro-l-ß-D-
ribofuranosyl benzimidazole (DRB) or the translation inhib-
itor cycloheximide (CHX) is associated with rapidly increased 
expression of Bcl-xs [10]. In this study, the effects of dexame-
thasone (Dex) on bcl-x gene expression and apoptosis in 
TMK-1 cells induced by transcription and translation inhib-
itors were studied. We showed that Dex efficiently suppresses 
cell apoptosis by stabilization of bcl-x mRNA, increasing the 
BC1-XL level, and inhibition of apoptosis-associated upregula-
tion of Bcl-xs expression. 
2. Materials and methods 
2.1. Materials 
Dulbecco's modified Eagle's medium (DMEM) and fetal bovine 
serum (FBS) were obtained from Gibco (Grand Island, NY, USA). 
Culture plasticware was purchased from Costar (Cambridge, MA, 
USA). [a-32P]dCTP (6000 Ci/mmol) was purchased from Dupont 
NEN (Boston, MA, USA). The 32P-labeled cDNA probes were pre-
pared by random primer extension with [a-32P]dCTP to a specific 
activity of about 108 cpm^lg of DNA. The cDNA templates for 
bcl-xL/S were obtained by RT-PCR from total RNA of TMK-1 cells. 
Antibodies against human Bcl-2, Bax, Bak, and BC1-XL/S were pur-
chased from Oncogene Sciences (Uniondale, NY, USA) and Santa 
Cruz Biotech (Santa Cruz, CA, USA). DRB, ActD and CHX were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). RU486 was 
generously provided by Uclaf, France. All other chemicals used 
were purchased either from Sigma or from E. Merck (Darmstadt, 
Germany). 
2.2. Cell culture 
The cultured human gastric carcinoma cell line TMK-1, derived 
from a poorly differentiated adenocarcinoma [11], was a generous 
gift from Dr. Eiichi Tahara (Hiroshima University, Japan). This cell 
line carries a mutated form, G to A point mutation at codon 173, of 
the p53 gene (mp53) as described [12]. None of the bcl-2 mRNA or 
protein was detected in the cells in previous studies [10,13]. In this 
study, TMK-1 cells were cultured at 37°C in DMEM medium supple-
mented with 15 mM HEPES, 26 mM sodium bicarbonate, 2 mM L-
glutamine, 100 μg/ml streptomycin, 100 U/ml penicillin, and 10% 
charcoal-dextran treated FBS with 5% CO2. The growth curve of 
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the cells was determined by counting the viable cells with trypan blue 
exclusion. Cells in the logarithmic growth phase were used in this 
study. The cells were seeded into culture dishes and allowed 24 h prior 
to treatment. ActD (100 ng/ml), DRB (25 Hg/ml), CHX (2 μ&ΊηΙ), 
dexamethasone (10~6 M), and RU486 (10~6 M) were added to the 
medium as a concentration stock in ethanol. Control cells were fed 
with medium containing the same amount of ethanol. 
2.3. Analysis of DNA fragmentation 
Treated or untreated TMK-1 cells were lysed with 0.5 ml lysis 
buffer (5 mM Tris-borate (pH 8.0), 0.25 ml Nonidet P-40, and 
1 mM EDTA), followed by the addition of RNase (20 μg/ml), and 
incubated at 37°C for 1 h. Cells were further treated with proteinase 
K (300 μg/ml) for an additional 1 h, and DNA was then isolated. The 
DNA was resuspended in 10 mM Tris-Cl buffer (pH 8.0) containing 
1 mM EDTA and quantified. The same amount of DNA of each 
sample was loaded and electrophoresed in a 1.5% agarose in Tris-
borate buffer (pH 8.0) containing 1 mM EDTA. 
2.4. Western blot analysis 
TMK-1 cells were plated on 6 cm dishes at a density of 1 X 106 cells/ 
dish for 24 h prior to Dex treatment. After another 48 h, the Dex 
treated or untreated cells were incubated with DRB (25 μg/ml), ActD 
(100 ng/ml) or CHX (2 μg/ml) for the indicated time periods. Whole 
cell extract preparation and SDS-PAGE were performed as described. 
Immunoblotting was performed using rabbit anti-human antibodies 
for Bcl-2, Bax, Bak, and BC1-XL/S· Signals were visualized with an 
enhanced chemoluminescence kit (ECL, Amersham, UK) followed 
by exposure to X-ray films. 
2.5. Isolation of RNA and Northern blot analysis 
Total RNA isolation and Northern blot analysis were performed 
essentially as described [14]. For Northern analysis, 30 μg of total 
RNA was size fractionated, transferred to nylon filters, hybridized, 
and autoradiographed. Autoradiography results were quantified and 
normalized with respect to glyceraldehyde 3-phosphodehydrogenase 
(GAPDH) mRNA as determined by hybridization analysis. 
2.6. Flow cytometric analysis 
Hypodiploid DNA was analyzed using the method of propidium 
iodide (PI) staining and flow cytometry as described [15], Briefly, drug 
treated or untreated cells (1 X106) were washed and resuspended in 
1 ml hypotonic fluorochrome solution (50 μg/ml of PI in 0.1% sodium 
citrate plus 0.1% Triton X-100). Samples were placed at 4°C in the 
dark, and the PI fluorescence of individual nuclei was analyzed using 
a FACScan flow cytometer (Becton Dickinson, Lincoln Park, NJ). 
Cellular debris was excluded from analysis by raising the forward 
scatter threshold, and the DNA content of intact nuclei was registered 
on a logarithmic scale. Apoptotic cell nuclei containing hypodiploid 
DNA emitting fluorescence in channels 10-400 were enumerated as a 
percentage of the total population. 
3. Results 
3.1. Dex decreases the susceptibility of TMK-1 cells to 
apoptosis 
To study the role of Dex on TMK-1 cell apoptosis, the 
effects of Dex on cell proliferation and morphology were first 
assessed. Although Dex inhibits cell proliferation in a number 
of cultured cells, the growth of TMK-1 cells was not influ-
enced by 1CT6 M Dex. No significant differences in cell via-
bility and total cell number were observed in cells treated with 
or without Dex for 48 h although the cells were more flattened 
in the presence of Dex (data not shown). These observations 
indicate that Dex does not produce toxic effects on cell pro-
liferation and morphology. 
Treatment of TMK-1 cells with Dex for 48 h markedly 
decreased the susceptibility of the cells to apoptosis and the 
onset of apoptosis was also delayed. The observed apoptosis 
was characterized by chromatin condensation, nuclear frag-
mentation, and formation of apoptotic bodies under the fluo-
Fig. 1. Dex suppressed apoptosis triggered by transcription and 
translation inhibitors. TMK-1 cells (1X106) were plated into 6 cm 
culture dishes and incubated with or without Dex (10~6 M) for 48 
h. The cells were then treated in the absence (control) or presence 
of (A) ActD; (B) DRB or CHX for the time indicated before being 
harvested and stained with PI. Hypodiploid DNA peaks corre-
sponding to apoptotic nuclei were revealed by cytofluorometry as 
described in Section 2. 
rescent microscope as previously described [10]. In this study, 
cell apoptosis was assessed by DNA fragmentation and the 
manifestation of the broad hypodiploid DNA peak in flow 
cytometric analysis. Results shown in Fig. 1A indicate that 
the number of apoptotic cells in the TMK-1 population 8 h 
after ActD treatment was 40.9% but decreased to 13.5% when 
cells were coincubated with ActD and Dex. Dex alone had no 
effect on the background apoptotic cell population of the 
TMK-1 cells (Fig. 1A). Marked suppression of apoptosis by 
Dex was also demonstrated in apoptosis triggered by DRB 
and CHX (Fig. IB). Results shown in Fig. 2 indicate that the 
absence or presence of hypodiploid peaks closely parallels the 
absence or presence of DNA ladder in variously treated cells. 
The relative intensity of DNA ladder was much evident in 
ActD treated cells than cells cocultured with Dex and ActD 
(Fig. 2, lanes 3 and 5). Furthermore, the protective effect of 
Dex was completely abolished by the presence of the gluco-
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Fig. 3. Effects of ActD and Dex on Bcl-xL/S, Bax, and Bak expres-
sion. TMK-1 cells were pretreated in the absence (lanes 1-5) or 
presence (lanes 6-10) of Dex for 48 h and ActD was then added for 
the time indicated. Whole extract (30 μg) of cells were analyzed by 
immunoblotting as described in Section 2. The immunoblots shown 
here represent the typical result from several independent experi-
ments. 
Fig. 2. Internucleosomal DNA fragmentation induced by ActD. 
TMK-1 cells (1X 106) were plated into 6 cm culture dishes and incu-
bated with or without Dex (10~β Μ) for 48 h. The cells were then 
treated in the absence (lane 2) or presence of ActD, Dex, ActD plus 
Dex, ActD plus Dex plus RU486, RU486, or ActD plus RU486 
(lanes 3-8, respectively); lane 1 is the 100 bp DNA ladder. 
corticoid receptor (GR) antagonist RU486, which suggests a 
GR-mediated mechanism in the action of Dex (Fig. 2, lanes 5 
and 6). DNA fragmentation in DRB or CHX treated cells was 
similarly modulated by Dex and RU486 (data not shown). 
Taken together, these results clearly demonstrate that gluco-
corticoid efficiently suppresses the apoptosis of TMK-1 cells 
triggered by transcription and translation inhibitors. 
Northern blot analysis in the first 8 h after ActD treatment. 
Since it was shown that over 99% of total RNA synthesis was 
blocked in ActD treated (50 ng/ml) TMK-1 cells, the relative 
intensity of the bcl-x mRNA levels can be used to calculate 
the stability of bcl-x mRNA [10]. As shown in Fig. 4A, a 
single bcl-x mRNA band about 2.7 kbp was detected in 
TMK-1 cells which declined rapidly with time upon ActD 
treatment. When ActD was added to Dex treated cells, the 
turnover rate of bcl-x mRNA was significantly decreased com-
pared to that observed when ActD was added to Dex un-
3.2. Dex suppresses the upregulation of Bcl-xs in apoptotic 
cells 
To study the effect of Dex on the level of Bcl-2 related 
proteins, we examined the alterations of Bcl-x, Bax, and 
Bak in the cells during apoptosis. Although TMK-1 cells ex-
press a relatively high level of BC1-XL, Bax, and Bak proteins, 
both bcl-2 mRNA and protein were not detectable in the cells 
[10,13]. The changes in the Bcl-x, Bax, and Bak protein levels 
in response to ActD are summarized in Fig. 3. The basal level 
of BC1-XL protein was significantly increased after 48 h treat-
ment with Dex (Fig. 3, lanes 1 and 6). Consistent with our 
earlier findings, the apoptosis triggered by ActD is associated 
with overexpression of Bcl-xs in TMK-1 cells (Fig. 3, lanes 1-
5). Interestingly, pretreatment of the cells with Dex abolished 
or delayed the increase of Bcl-xs associated with ActD treat-
ment (Fig. 3, lanes 6-10). In contrast to changes in Bcl-xs and 
BC1-XL, the Bax and Bak proteins displayed few changes dur-
ing ActD treatment in the cells. In a similar manner, pretreat-
ment of Dex suppressed or delayed the overexpression of Bcl-
xs in the DRB or CHX treated cells (data not shown). These 
results demonstrate that the susceptibility of TMK-1 cells to 
apoptosis triggered by these inhibitors was associated with the 
relative level of Bcl-xg in the cells. In addition, Dex attenuated 
cell apoptosis through increase in the expression of BC1-XL and 
blocked the pathway for Bcl-xs overexpression. 
3.3. Dex increases the stability of bcl-x mRNA 
The steady-state levels of bcl-x mRNA were investigated by 
Fig. 4. Effects of ActD and Dex on bcl-x mRNA levels. TMK-1 
cells were pretreated in the absence (lanes 1-5) or presence (lanes 6-
10) of Dex for 48 h and ActD was then added for the time indi-
cated. A: Total RNA (30 μg) from each sample was prepared, frac-
tionated, transblotted, hybridized, and autoradiographed. B: Densi-
tometric quantitation of the bcl-x mRNA level in each sample using 
the level of GAPDH transcript as the normalization control. The re-
sults are the average of two separate experiments. 
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treated cells (Fig. 4A). In addition, when cells were pretreated 
with Dex, the steady-state level of bcl-x mRNA was upregu-
lated to about 1.5-fold over the control level in Dex untreated 
cells (Fig. 4A, lanes 1 and 6). The bcl-x mRNA exhibited an 
about 2-fold increase in stability after exposure to Dex as the 
apparent half-lives of bcl-x mRNA increased from about 3.5 h 
to 8 h (Fig. 4B). The bcl-x mRNA bands shown in Fig. 4 
consist of bcl-XL and bcl-xs transcripts since the difference in 
size between bcl-xi and bcl-xs transcripts is too small for 
them to be distinguished. Nevertheless, the bcl-xi transcript 
should mainly account for the bcl-x mRNA signals because of 
the much greater abundance of basal BC1-XL than of Bcl-xs 
proteins (Fig. 3, lanes 1 and 6) and there is no transcription in 
the presence of ActD. These results indicate that Dex also 
modulates bcl-x gene expression at the posttranscriptional lev-
el. 
4. Discussion 
Glucocorticoids play a fundamental role in normal develop-
ment and physiological control of animals by modulating pro-
liferation of various normal and malignant cells [16]. Gluco-
corticoids have been employed as potent anti-inflammatory 
agents for years, yet the mechanisms remain to be elucidated. 
The glucocorticoids bind specifically to the glucocorticoid re-
ceptor and modulate gene expression such as activation or 
inhibition of transcription of specific genes. Glucocorticoids 
have been shown to induce irreversible Gl arrest and cell 
death in a human lymphoblastic leukemic T-cell line (CEM-
C7) [17]. Clinically, they have been used in the treatment of 
lymphoid leukemia and lymphoma. The mechanism underly-
ing this effect is the induction of cell apoptosis [18]. In rodent 
thymocytes, glucocorticoid-induced apoptosis is a model sys-
tem for research of programmed cell death [19]. In this study, 
however, we show that Dex decreases the susceptibility of 
TMK-1 cells to transcription and translation inhibitor in-
duced apoptosis. Our results are in accordance with the find-
ing that glucocorticoids are known to prolong the life-time 
and inhibit apoptosis of neutrophils [20,21]. In Ml myeloid 
leukemic cells and human mammary luminal epithelial cells, 
treatment with glucocorticoids also resulted in a decrease in 
the susceptibility of the cells to apoptosis inducing agents 
[22,23]. The result that the GR antagonist RU486 completely 
abolished the suppressive effect of Dex on DNA fragmenta-
tion confirms that the protective effect of Dex to the cells is 
mediated through a GR dependent pathway (Fig. 2). Consis-
tent with studies in neutrophils and leukemia cells, however, 
Dex delayed, rather than blocked, apoptosis which resulted in 
prolonged TMK-1 cell survival [20-23]. 
The susceptibility of TMK-1 cells to apoptosis in treatment 
with transcription and translation inhibitors may be due to 
the absence of Bcl-2 and the expression of Bcl-xs protein in 
the cells [10,13]. In this study, treatment of TMK-1 cells with 
Dex inhibited or delayed endogenous Bcl-xs overexpression 
observed during cell apoptosis (Fig. 3). Since the increased 
expression of Bcl-xs was shown to be associated with the 
onset of cell apoptosis [9,10], our results demonstrate that 
the suppression of TMK-1 cell apoptosis by Dex is mediated 
through inhibition of Bcl-xs overexpression. Dex was also 
shown to downregulate bcl-xs gene expression in rat thymo-
cytes which led to the suggestion that Bcl-xs may favor the 
survival of thymocytes [24]. Consistent with the increased ex-
pression of BC1-XL protein (Fig. 3), significant increases in 
steady-state bcl-x mRNA levels were also shown in Dex 
treated cells (Fig. 4). The enhanced bcl-XL mRNA stability 
and protein levels may represent a part of the mechanism 
underlying the protective effect of Dex. Stabilization of 
mRNA transcripts is common for various genes which are 
regulated by glucocorticoids [25,26]. Suppression of suscepti-
bility of Ml myeloid cells to apoptosis by Dex was shown to 
be associated with an enhanced steady-state level of bcl-xi 
mRNA [22]. 
In conclusion, the expression of the bcl-x gene in TMK-1 
cells is regulated at both posttranscriptional and translational 
levels by Dex. Results shown in this study indicate that 
modulation of bcl-x gene expression is related to the suscept-
ibility of TMK-1 cells to apoptosis. The anti-apoptotic ef-
fects of glucocorticoids in cells such as TMK-1 may thus 
be related to the modulation of bcl-x gene expression in the 
cells. 
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